CD19 and B-cell chronic lymphocytic leukemia: Phase 1 and 2 trials with CD19-CAR-engineered NK cells have shown impressive responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL).